Specialty Pharma Is Top of Mind for PBM Execs in Earnings Calls

While the cost-saving potential of biosimilars was an overarching theme as the major PBMs’ parent companies discussed second-quarter 2021 earnings, “specialty” was the buzzword during the most recent round of conference calls regarding fourth-quarter and full-year 2021 financial results.

“I would definitely say that the specialty [pharmacy] and home delivery business are contributing to earnings and our margin,” said Heather Cianfrocco, CEO of UnitedHealth Group-owned PBM OptumRx, during a Jan. 19 call with analysts.

© 2023 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

pills-in-hands
June 8

Buprenorphine Coverage Is Improving, but Access Barriers Remain

READ MORE
a-businessman-touching-tablet-screen
June 8

CVS Exec Says Employers ‘Shape the Economics’ of PBMs

READ MORE
an-old-lady-at-the-pharmacy
June 8

Community Pharmacist Group Greets Optum Rx Programs With Cautious Optimism

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today